The secretome of umbilical cord-derived mesenchymal stem cells (UC-MSCs) — encompassing soluble paracrine factors and extracellular vesicles — demonstrates multi-pronged activity against osteoarthritis pathology. In vitro, it restores anabolic chondrocyte phenotype while suppressing catabolic enzymes MMP-13 and ADAMTS-5, the principal collagen and aggrecan destroyers in cartilage degradation, and attenuates NF-κB and MAPK pro-inflammatory signaling. Preclinical intra-articular delivery preserved cartilage architecture and reduced synovial inflammation, with early clinical reports showing pain and function improvements.
This review consolidates a mechanistically coherent rationale for secretome-based OA therapy at a moment when the field is actively seeking disease-modifying alternatives to corticosteroids and hyaluronic acid. Targeting the secretome rather than live cell engraftment sidesteps critical challenges: immune rejection risk, manufacturing inconsistency, and regulatory complexity around living cellular products. The specific identification of MMP-13 and ADAMTS-5 suppression is clinically meaningful — both enzymes are established drivers of irreversible cartilage loss with no approved small-molecule inhibitors in orthopedics.
However, several cautions temper enthusiasm. This is a narrative review, not a primary trial. Available clinical data conflates whole MSC therapy with secretome-specific interventions, an important distinction since paracrine output varies dramatically by cell passage, donor age, and manufacturing conditions. Standardization of extracellular vesicle dosing remains unsolved. Until adequately powered RCTs with imaging endpoints emerge, this represents a biologically compelling but clinically unproven approach — incremental progress with genuine paradigm-shifting potential.
